ACH-1625 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C
NEW HAVEN, Conn., Jan. 4, 2012 (GLOBE NEWSWIRE) — Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, announced today the receipt of a Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACH-1625 for the treatment of chronic hepatitis C virus (HCV). ACH-1625 is a once-daily protease inhibitor with broad genotypic coverage against HCV that was discovered by Achillion and is currently being evaluated in a Phase 2 clinical trial.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.